E Fund Management Co., Ltd. - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 169 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2022. The put-call ratio across all filers is 0.65 and the average weighting 0.3%.

Quarter-by-quarter ownership
E Fund Management Co., Ltd. ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$233
-37.9%
8,465
-23.4%
0.02%
-40.0%
Q2 2023$375
+25.8%
11,052
+33.6%
0.03%
+36.4%
Q1 2023$298
-11.0%
8,271
+10.1%
0.02%
-21.4%
Q4 2022$335
-99.9%
7,511
-47.4%
0.03%
-24.3%
Q3 2022$401,000
+4.7%
14,278
+0.5%
0.04%
+5.7%
Q2 2022$383,000
+43.4%
14,200
+81.2%
0.04%
+288.9%
Q1 2022$267,0007,8380.01%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q1 2022
NameSharesValueWeighting ↓
Kynam Capital Management, LP 3,200,000$88,064,00014.40%
Octagon Capital Advisors LP 759,898$20,912,3933.21%
TSP Capital Management Group, LLC 251,695$6,926,6452.67%
5AM Venture Management, LLC 310,270$8,538,6302.46%
COMMODORE CAPITAL LP 706,665$19,447,4212.27%
ACUTA CAPITAL PARTNERS, LLC 122,341$3,366,8242.26%
Redmile Group, LLC 1,635,938$45,021,0142.14%
RTW INVESTMENTS, LP 3,463,201$95,307,2922.01%
Eversept Partners, LP 588,143$16,185,6951.37%
Affinity Asset Advisors, LLC 150,000$4,128,0001.16%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders